Prospective Multicenter Single-Arm Study of Vanquish Water Vapor Ablation for PrOstate CanceR (VAPOR 2 Study)

Go Back to All Clinical Trials

Prospective Multicenter Single-Arm Study of Vanquish Water Vapor Ablation for PrOstate CanceR (VAPOR 2 Study)

Brief description of study

The purpose of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation Device (“Vanquish”) in subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.

Clinical Study Identifier: s23-00203

ClinicalTrials.gov Identifier: NCT05683691

Principal Investigator: Samir Taneja.

Other Investigator: James S Wysock.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies